Locally Advanced or Metastatic Solid Tumors
Conditions
Keywords
Solid Tumors
Brief summary
This is a Phase 1/2, open-label, dose escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of BC3195 in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors.
Detailed description
This is a Phase 1/2, open-label, dose escalation and expansion study to assess the safety, pharmacokinetics, and preliminary efficacy of BC3195 in combination with pembrolizumab in participants with locally advanced or metastatic solid tumors. This study consists of two parts: A dose escalation part (Part 1) and a dose expansion part (Part 2). Each part will include a screening period, a treatment period, and follow-up period.
Interventions
DRUGBC3195
BC3195 for injection is a sterile lyophilized powder in a 20 mg single-dose vial. Administration: Administered via intravenous (IV) infusion, with dosing and frequency determined according to Phase I (dose escalation) and Phase Ⅱ(dose expansion) study design
Pembrolizumab will be administered at 200 mg as a 30 minute IV infusion Q3W prior to BC3195. Sites should make every effort to target infusion timing to be as close to 30 minutes as possible.
Sponsors
Biocity Biopharmaceutics Co., Ltd.
Merck Sharp & Dohme LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Provide written informed consent. 2. Aged at least 18 years at the time of ICF signature. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to the first dose of study treatment. 4. Life expectancy of ≥ 3 months based on the Investigator's assessment. 5. Participants in Dose escalation part must meet the following criteria: Histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report and have received, or been intolerant to, all treatment known to confer clinical benefit, including but not limited to: NSCLC, BC, HNSCC, ESCC, EMC, UC, CRC, OC, and prostate cancer. The sponsor or designee must approve eligibility for malignancies other than those specifically mentioned above. 6. Participants in Dose expansion part must meet one of the following criteria: 1. For NSCLC (cohort 1): Participants have pathologically documented Stage IIIB, IIIC, or Stage IV NSCLC without actionable genomic alterations (AGA) based on the American Joint Committee on Cancer, Eighth Edition (Participants must have documented negative test results for EGFR and ALK genomic alterations and have no known genomic alterations in ROS1, NTRK, BRAF, MET exon 14 skipping, or RET) and meet one of the following criteria: 1. Locally advanced or metastatic NSCLC participants relapsed or refractory to at least 1 prior line of therapy including platinum-based chemotherapy in combination with or without anti-PD(L)1 antibody; OR 2. Locally advanced or metastatic NSCLC participants relapsed or refractory to at least 2 prior lines of therapy including anti-PD(L)1 antibody and platinum-based chemotherapy sequentially. 2. For TNBC (cohort 2): Participants have histologically or cytologically confirmed TNBC per ASCO/CAP criteria based on the most recent analyzed biopsy or other pathology specimen and meets the following criteria: Relapsed or refractory to 2 or more prior systemic regimens for unresectable, locally advanced or metastatic disease (-For prior therapy, 1 could be in the (neo)adjuvant setting, provided progression occurred during treatment or within 12 months after treatment discontinuation;-Received taxane(s) in any setting). 3. For HNSCC (cohort 3): Participants have histologically or cytologically confirmed locally advanced or metastatic HNSCC and meet one of the following criteria: 1. Relapsed or refractory to at least 1 prior line of therapy including platinum-based chemotherapy with cetuximab, or platinum-based chemotherapy with or without anti-PD(L)1 antibody. OR 2. Disease progression while on or after at least 2 prior lines of therapy including anti-PD(L)1 antibody and platinum-based chemotherapy sequentially. 4. For Other solid tumors (cohort 4): Participants with other solid tumors and meets the following criteria: 1. Histologically or cytologically confirmed locally advanced or metastatic solid tumors (e.g., ESCC, EMC, UC, CRC, OC, prostate cancer or tumors with observed efficacy signal during the dose escalation part). 2. Participants refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition. 7. Participants with at least one measurable lesion according to RECIST v1.1 as assessed by the local site investigator/radiology. 8. Participants with adequate organ function. 9. Agree to provide previously archived tumor tissue samples, or newly obtained biopsy of a previously unirradiated tumor lesion (optional for dose escalation part). Formalin-fixed, paraffin-embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue. Details pertaining to tumor tissue collection can be found in the Laboratory Manual. 10. Males and females of child-bearing potential must agree to use effective contraception (e.g., oral contraceptives, intrauterine devices, abstinence, or barrier contraceptives combined with spermicides) from the time ICF signature until 6 months after the last dose. Females of childbearing potential include those who are premenopausal and those who are 2 years postmenopausal.
Exclusion criteria
1. Has received prior systemic anticancer treatment, including investigational agents, within 5 half-lives or 4 weeks prior to the first dose of study treatment (whichever is shorter). Has received Traditional Chinese Medication within 7 days prior to study treatment. 2. Participants who have received major surgery (defined as requiring general anesthesia and \>24-hour inparticipant hospitalization) within 4 weeks prior to the first dose of study treatment. Participant must have recovered adequately from complications from the intervention prior to starting study treatment. 3. Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis. Note: Participants must have recovered from all radiation-related toxicities and not require corticosteroids. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease. 4. Has had an allogeneic tissue/solid organ transplant. 5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. 6. Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment. 7. Has clinically uncontrolled pericardial effusion, pleural effusion, or ascites at screening. 8. Has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease. 9. Active viral infection requiring systemic therapy during the screening period. 10. Hypertension that cannot be well-controlled with medical treatment. Not well-controlled is defined as systolic blood pressure \>150 mmHg or diastolic blood pressure \>95 mmHg (adjustment of hypertensive medication prior to study initiation is permitted, but the mean of the most recent three consecutive blood pressure records prior to study entry must be ≤150/95 mmHg \[with at least 2- minute interval between each measurement\]). 11. Cardiovascular disease of clinical significance: Including New York Heart Association \[NYHA\] Class II-IV, congestive heart failure, second-degree or higher heart block, myocardial infarction within the past 3 months, unstable arrhythmia or unstable angina, marked QT interval prolongation (12-lead ECG showing baseline-corrected QTc interval \>480 ms), cerebral infarction within 3 months, or having received PTCA or CABG within 6 months. 12. Participants with active or chronic corneal disorders, with other active ocular conditions requiring ongoing therapy or with any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy. 13. Participants with any active infection that requires systemic anti-infective therapy judged by the investigators. 14. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded. Participants with low-risk early-stage prostate cancer (T1-T2a, Gleason score ≤6, and PSA \<10 ng/mL) either treated with definitive intent or untreated in active surveillance with stable disease are not excluded. 15. Grade 2 or higher peripheral neuropathy. Other toxicities caused by prior anti-tumor therapy has not recovered to ≤ grade 1 (per CTCAE 5.0) (except for alopecia, pigmentation, and other events judged by the Investigator to be tolerable) or the level specified by the inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of partcipants with Dose Limiting Toxicities (DLTs) | Throughout the dose escalation phase, an average of 1 year | The incidence of dose-limiting toxicity (DLT) at different doses of BC3195 combined with pembrolizumab in patients with locally advanced or metastatic solid tumors. DLT will be assessed at the end of Cycle 1. |
| Investigator-assessed Objective Response Rate (ORR) of BC3195 combined with pembrolizumab in participants with solid tumors | Throughout the dose expansion phase, an average of 2.5 years | ORR (per investigator's assessment based on RECIST v1.1) defined as the proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Investigator-assessed progression-free survival (PFS) of BC3195 combined with pembrolizumab in participants with solid tumors | Through study completion, an average of 2.5 years | PFS (per investigator's assessment based on RECIST v1.1) defined as the time interval from first dose to the first documented PD or death due to any cause, whichever occurs first. |
| Investigator-assessed disease control rate (DCR) of BC3195 combined with pembrolizumab in participants with solid tumors | Through study completion, an average of 2.5 years | DCR (per investigator's assessment based on RECIST v1.1) defined as the proportion of participants with a BOR of CR, PR, or stable disease (SD). |
| Investigator-assessed duration of response (DOR) of BC3195 combined with pembrolizumab in participants with solid tumors | Through study completion, an average of 2.5 years | DOR (per investigator's assessment based on RECIST v1.1) defined as the time interval from the first documentation of response (CR or PR) to the first documentation of PD or death, whichever occurred first. |
| Overall survival (OS) of BC3195 combined with pembrolizumab in participants with solid tumors | Through study completion, an average of 3 years | OS defined as the time interval from the first dose to death due to any cause. |
| Number of partcipants with treatment emergent adverse events (TEAEs) | Through study completion, an average of 3 year | To evaluate the incidence and severity of treatment emergent adverse events (TEAEs) of BC3195 and/or pembrolizumab based on NCI CTCAE v5.0. |
| Number of partcipants with treatment related adverse events (TRAEs) | Through study completion, an average of 3 year | To evaluate the incidence and severity of treatment related adverse events (TRAEs) of BC3195 and/or pembrolizumab based on NCI CTCAE v5.0. |
| Number of partcipants with serious adverse events (SAEs) | Through study completion, an average of 3 year | To evaluate the incidence and severity of serious adverse events (SAEs) of BC3195 and/or pembrolizumab based on NCI CTCAE v5.0. |
| To evaluate the concentration-time data for BC3195, total antibody, and payload | Through study completion, an average of 2.5 year | — |
| To characterize the PK parameter AUC of BC3195 | Through study completion, an average of 2.5 year | — |
| To Characterize the PK parameter Cmax of BC3195 | Through study completion, an average of 2.5 year | — |
| To characterize the PK parameter Ctrough of BC3195 | Through study completion, an average of 2.5 year | — |
| Assessment of CDH3/PD-L1 expression level in tumor tissue and the correlation between the expression level and the efficacy of BC3195 combined with pembrolizumab. | Through study completion, an average of 3 year | — |
| Assessment of the number of participants who are Anti-Drug Antibody (ADA)-positive at any time and who have a treatment-emergent ADA | Through study completion, an average of 3 year | — |
Countries
China
Contacts
CONTACTYilong Wu
CONTACTChongrui Xu
Outcome results
None listed